SCHEMBL23833536

SCHEMBL23833536

Cc1cc(NN)ncc1S(=O)(=O)NC1CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ BRD4 O60885 4/20 0.42
▸ BRD2 P25440 2/20 0.42
▸ BRD3 Q15059 2/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ ALOX5AP P20292 2/20 0.40
▸ FEN1 P39748 2/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ HPGD P15428 1/20 0.40
▸ KCNH2 Q12809 1/20 0.39
▸ MCOLN3 Q8TDD5 1/20 0.39
▸ TP53 P04637 1/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ MTOR P42345 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23833619 0.79 ALDH1A1 (0.47) HTTLMNAGAAMAPTTSHR
SCHEMBL25518530 0.77 KDM4E (0.33) LMNAGAAMAPTFEN1KDM4E
SCHEMBL30096914 0.77 PDIA6 (0.39) LMNAGAAMAPTALDH1A1PIK3C3
SCHEMBL30094638 0.77 L3MBTL1 (0.42) HTTLMNAGAAMAPTL3MBTL1
SCHEMBL23833549 0.77 PDIA6 (0.39) LMNAGAAMAPTALDH1A1PIK3C3
SCHEMBL23833547 0.77 L3MBTL1 (0.42) HTTLMNAGAAMAPTL3MBTL1
SCHEMBL25518454 0.74 CDK1 (0.37) HTTLMNAGAAMAPTL3MBTL1
SCHEMBL23833599 0.73 ALDH1A1 (0.48) LMNAGAAMAPTBRD4BRD2
SCHEMBL23833576 0.71 KDM4E (0.55) LMNAGAAMAPTTSHRL3MBTL1
SCHEMBL11963521 0.69 L3MBTL1 (0.63) HTTLMNAMAPTTSHRBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 — — US disclosed
EP-4121426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE Akebia Therapeutics Inc. (US) 2023-01-25 — — EP disclosed
CN-115515948-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2022-12-23 — — CN disclosed
WO-2021188938-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE HIF1AN, EGLN3, PHF20 HTT 3542/4885LMNA 4071/4885GAA 3851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback